Recombinant Human KIR2DL1 (C-6His)

Recombinant Human KIR2DL1 (C-6His)

Size1:10μg price1:$136
Size2:50μg price2:$378
Size3:500μg price3:$1890
SKU: PHH2403 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human KIR2DL1 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Killer Cell Immunoglobulin-like Receptor 2DL1 is produced by our Mammalian expression system and the target gene encoding His22-His245 is expressed with a 6His tag at the C-terminus.

Accession #

P43626

Host

Human cells

Species

Human

Predicted Molecular Mass

25.5 KDa

Buffer

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Form

Lyophilized

Shipping

The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

CD158 antigen-like family member A; CD158a antigen; CD158a;KIR2DL1; MHC class I NK cell receptor; Natural killer-associated transcript 1; NKAT; NKAT-1; p58.1 MHC class-I-specific NK receptor

 

Background

Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) is an inhibitory Natural Killer cell immunoglobulin-like receptor with two extracellular immunoglobulin domains. KIR2DL1 down-regulates the cytotoxicity of NK cells upon recognition of specific class I major histocompatibility complex (MHC) molecules on target cells. It has been reported that the KIR2DL1 is bound to its class I MHC ligand, HLA-Cw4. The KIR2DL1-HLA-Cw4 interface exhibits charge and shape complementarity. KIR/HLA-I interactions can act through inhibition of NKC activation by target cells and NKC licensing for greater intrinsic responsiveness.

 

Note

For Research Use Only , Not for Diagnostic Use.